Imagion Biosystems Limited
IBXXF
$0.01
$0.00-10.71%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -97.31% | -86.95% | -82.00% | -65.56% | -46.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -97.31% | -86.95% | -82.00% | -65.56% | -46.15% |
| Cost of Revenue | 416.77% | -27.21% | -80.39% | -87.78% | -92.41% |
| Gross Profit | -188.25% | -133.50% | -84.15% | 20.65% | 788.34% |
| SG&A Expenses | -44.76% | -71.21% | -81.00% | -77.19% | -74.74% |
| Depreciation & Amortization | -97.83% | -98.51% | -98.77% | -81.32% | -67.16% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35% | -62.53% | -82.36% | -80.76% | -79.74% |
| Operating Income | -362.95% | 28.52% | 82.74% | 90.31% | 93.72% |
| Income Before Tax | -104.72% | 23.72% | 65.89% | 77.71% | 83.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -104.72% | 23.72% | 65.89% | 77.71% | 83.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.72% | 23.72% | 65.89% | 77.71% | 83.63% |
| EBIT | -362.95% | 28.52% | 82.74% | 90.31% | 93.72% |
| EBITDA | -1,143.02% | 6.05% | 80.95% | 92.63% | 97.41% |
| EPS Basic | 72.51% | 86.78% | 90.90% | 87.96% | 86.72% |
| Normalized Basic EPS | 72.73% | 86.86% | 90.89% | 88.03% | 86.78% |
| EPS Diluted | 72.24% | 86.66% | 90.82% | 87.96% | 86.72% |
| Normalized Diluted EPS | 72.73% | 86.86% | 90.89% | 88.03% | 86.78% |
| Average Basic Shares Outstanding | 517.31% | 423.97% | 295.60% | 175.85% | 47.45% |
| Average Diluted Shares Outstanding | 517.31% | 423.97% | 295.60% | 175.85% | 47.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |